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Abstract: The effect of curcumin, a promising anticancer agent, on the action of certain cytostatic 
drugs, including etoposide, is not well understood. This paper examines the effect of curcumin on 
etoposide action in leukemic and normal bone marrow cells in vivo conditions. The experimental 
model used was Brown Norway rats with a transplantable acute promyelocytic leukemia. Leukemia 
was induced by intravenous injection of BNML (Brown Norway Myeloid Leukemia) cells. Curcumin 
was administered by oral gavage (200 mg/kg) for 23 consecutive days and etoposide was used in-
traperitoneally (50 mg/kg) for the last three days of the experiment. Control leukemic and healthy 
rats received the solvent for the tested compounds only. Curcumin significantly reduced the number 
of leukemic promyelocytes in the bone marrow of BNML rats in comparison to the leukemic control. 
Treatment with curcumin plus etoposide led to a decrease in the number of promyelocytes to the 
normal values occurring in healthy individuals. In contrast, the percentage of the normal precur-
sors of granulocytes (p <0.001) and erythrocytes (p <0.001) increased significantly in comparison to 
the group treated with only etoposide. The results of the study indicate that curcumin may protect 
healthy myeloid cells against the cytotoxic effect of etoposide and potentiate the antileukemic action 
of this anticancer drug.
Key words: curcumin, etoposide, acute myeloid leukemia, bone marrow, rats.
INTRODUCTION
Curcumin, is the main polyphenol derived from rhizomes of the plant Curcuma 
longa. Curcumin exhibits a number of biological activities including anti-inflam-
matory, antioxidant, metabolism regulating, antifungal, antiparasitic, antibacteri-
al and anticancer [1–4]. It has potent anticancerous activity in the cells of both 
solid tumors and leukemias [5]. The anticancer effect of curcumin depends on 
stimulation of apoptosis in malignant cells and inhibition of their proliferation 
[6, 7]. Curcumin may potentially inhibit the growth of leukemia cells by interfering 
in epigenetic phenomena. It unlocks hypermethylation which inactivates tumor 
suppressor genes in acute myeloid leukemia (AML) cells, leading to inhibition of 
leukemic cell growth in vitro and in vivo [8].
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On the other hand, curcumin demonstrates low toxicity in normal cells [9]. It 
has also ability to protect normal cells from the toxic effects of chemotherapy [5]. 
It is believed that one of the reasons for such contrasting actions of curcumin 
are the differences in metabolism between cancer and normal cells [10]. For ex-
ample, tumor cells are characterized by the preponderance of glycolysis over the 
aerobic metabolism and they also produce a lot of lactate, leading to acidosis in 
an extracellular environment acting as an immunosuppressive and promoting tu-
mor growth [11]. Curcumin can reverse the altered metabolism of cancer cells by 
affecting the expression of glucose transporters and the production of lactate [12]. 
Cancer cells often have a high level of free radicals, in contrast to their low lev-
els in normal cells [13]. Curcumin may exert increased prooxidant activity in 
the presence of a high level of free radicals, which are often present in tumor 
cells, and can stimulate these cells to apoptosis [14–16]. All the traits make 
a curcumin a promising anticancer compound that could be used in combina-
tion with conventional cytostatic drugs to protect healthy cells and/or enhance 
the therapeutic effects of anticancer drugs in cancer cells. 
Other studies have shown that curcumin can exert a synergistic effect with 
cytostatics such as 5-fluorouracil, vincristine, paclitaxel, cisplatin or etoposide in 
cancer cells [5]. On the other hand, there are reports demonstrating an opposite 
antagonistic effect of this polyphenol with etoposide [17].
The effect of curcumin on the action of etoposide in cancer cells is, therefore, not 
well understood. Etoposide is used to treat certain solid tumors, as well as leuke-
mias and lymphomas [18]. Previously, our own in vitro studies have demonstrated 
a synergistic effect of curcumin with etoposide in a rat myeloid leukemia LT-12 
cell line [19]. These results require confirmation in an appropriate in vivo model. 
The aim of this study was to determine the effect of curcumin on the action 
of etoposide in leukemic and normal bone marrow cells of Brown Norway rats 
with acute promyelocytic leukemia.
MATERIALS AND METHODS
Male Brown Norway (BN/CrlCmd) rats were purchased from the Animal Center, 
Polish Academy of Sciences Medical Research Center (Warsaw, Poland). The rats 
were kept under standard conditions of 22oC and 50–60% humidity, with a 12:12 h 
light-dark cycle. They were fed a synthetic pellet diet without plant polyphenols 
(Morawski Label Feed, Kcynia, Poland) and had free access to water.
BNML was induced in BN rats by intravenous inoculation of spleen-derived 
BNML cells (1 × 106 cells in 0.5 ml of sterile PBS injected into the tail vein). Cells 
were provided by Professor A.C.M. Martens, Utrecht University, the Netherlands 
[20]. Experiments were performed in accordance with animal testing regulations, 
under a license granted by the Jagiellonian University Ethical Committee.
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BNML is a transplantable myeloid leukemia originally induced by several 
injections of dimethylbenzoanthracene [20]. This leukemia is characterized by 
a slow progression and constant rate of growth. Similarities between BNML and 
human AML include the sensitivity of rat leukemia cells to chemotherapy, inhi-
bition of normal hematopoiesis and growth pattern [21]. This model was used to 
optimize drug dosage and to test the combinations of drugs used in AML. BNML 
rats were also used to test the methods of detection and treatment of minimal 
residual disease (MRD) [21].
The rats were divided into four groups of eight animals per group. Curcumin 
(Sigma-Aldrich Co. St. Louis, Missouri, USA) was administered by oral gavage at 
a dose of 200 mg/kg b.w. The dose of curcumin per rat was dissolved in 100 μl 
of DMSO Sigma-Aldrich Co. (St. Louis, Missouri, USA) and then diluted in 400 μl 
of corn oil Sigma-Aldrich Co. (St. Louis, Missouri, USA). Curcumin was adminis-
tered once a day from the second day after the inoculation of BNML cells, until 
day 23 of the experiment. The doses of curcumin was chosen based on previous 
studies in which this polyphenol significantly increased apoptosis of cancer cells 
in vivo [22]. Etoposide (Bristol-Myers Squibb, Sermoneta, Italy) was administered 
intraperitoneally at a dose of 50 mg/kg b.w. once a day for the last three days of 
the experiment. The dose of etoposide was chosen based on the study by Turner 
et al. [23], in which this chemotherapeutic agent induced a significant cyto-geno-
toxic effect in the bone marrow of mice. Control BNML and healthy rats were 
treated with vehicles only. 
The rats were killed by cervical dislocation under vetbutal anesthesia. The 
right femur was excised immediately after euthanasia and the bone was split 
longitudinally. Bone marrow was extracted from the femoral cavity using a small 
paintbrush moistened with FBS (Population Association of America, Pasching, 
Austria) and smears were prepared on glass slides. Smears were dried at room 
temperature, and then they were stained using May-Grünwald and Giemsa stain 
(Stamar, Gliwice, Poland). Stained smears were analyzed by counting approxi-
mately 500 cells/slides on three slides from each rat using an Olympus CX-40 
microscope (Olympus, Tokyo, Japan). 
Statistical significance between groups was determined using the one-way 
analysis of variance (ANOVA) and Tukey post hoc test. Data were expressed as 
mean ± standard deviation (SD).
RESULTS 
The predominant cells in the bone marrow of BNML rats were leukemic promyelo-
cytes, which prevailed over other granulocytic precursors and mature granulocytes 
and other bone marrow cells, such as erythroid cells, lymphocytes and mono-
cytes (Table 1, Fig. 1). A significant decrease was observed in the percentage of 
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T a b l e  1
Percentage of cells isolated from bone marrow of healthy control and leukaemic rats. 
Group 
of 
rats
Promyelocytes
(%)
Granulocytic 
precursors 
(myeloblasts, 
myelocytes,  
metamyelocyt- 
es, bands) (%)
Erythroid 
nucleated 
cells  
(%)
Mature  
granulocytes 
(%)
Monocytes 
(%)
Lymphocytes 
(%)
H  4,0 ± 1,6e 15,6 ± 0,6a 34,7 ± 1,6a 33,0 ± 2,2a  2,0 ± 0,8a,c  18,2 ± 2,9a,c
B 60,1 ± 4,1c  6,7 ± 1,5b  2,8 ± 0,8b  8,6 ± 2,0b  1,0 ± 0,1a,c  12,2 ± 1,3b,c
C 27,3 ± 4,0d 10,9 ± 1,2c  5,8 ± 0,9b  14,0 ± 3,6b,c 0,3 ± 0,5a  6,6 ± 2,9b
E 11,6 ± 1,7b  3,5 ± 2,4d  5,0 ± 2,8b  20,0 ± 4,9c,d 0,5 ± 0,7a 24,5 ± 4,3a
C+E   7,8 ± 2,6b,e  11,9 ± 2,4a,c 17,4 ± 3,5c  27,0 ± 9,2a,d  2,5 ± 1,7b,c 22,8 ± 7,0a
H, Healthy control rats; B, control leukaemic rats, C, leukemic rats treated with curcumin (200 mg/kg b.w.); 
E, leukaemic rats treated with etoposide (50 mg/kg b.w.); C+E, leukemic rats treated with curcumin (200 mg/kg b.w.) 
and etoposide (50 mg/kg b.w.). Data are presented as the mean percentage of each cell population ± standard 
deviation of the mean. Means having different signs (a, b, c, d) in the same column differ significantly, p <0.05
normal granulocytic precursors (p <0.001) and nucleated erythroid cells (p <0.001) 
in comparison to healthy individuals (Table 1). The decrease in granulocytic precur-
sors correlated with a decrease in the number of mature granulocytes (p <0.001) 
in BNML rats compared to healthy individuals (Table 1). However, insignificant 
differences were observed in the ratio of lymphocytes and monocytes between the 
group of leukemic and healthy rats.
Etoposide treatment led to a significant decrease in the number of leukemic 
promyelocytes (p <0.001) and normal granulocytic precursors (myeloblasts, my-
elocytes, metamyelocytes and bands) (p <0.05) compared to the control leukemic 
rats (Table 1). In contrast, the percentage of mature granulocytes (p <0.01) and 
lymphocytes (p <0.001) significantly increased after etoposide treatment in com-
parison to control leukemic rats (Table 1). These mature cells dominated in the 
bone marrow of etoposide-treated rats (Fig. 1). However, there were insignificant 
differences in the amount of nucleated erythroid cells and monocytes between 
the group treated with etoposide and control leukemic rats.
The administration of curcumin also led to a significant decrease in the per-
centage of leukemic promyelocytes (p <0.001), with a concomitant significant in-
crease in the percentage of normal granulocytic precursors (p <0.05) compared 
to control leukemic rats (Table 1). A clear, although insignificant, trend could be 
observed towards an increase in the percentage of nucleated erythroid cells and 
mature granulocytes in curcumin-treated rats compared to the control. There 
was also an insignificant change in the number of monocytes and lymphocytes 
after curcumin administration in comparison to control leukemic rats (Table 1). 
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It should be noted that a substantial percentage of death cells were observed 
in the bone marrow of curcumin or etoposide experimental groups. In compar-
ison to other groups of rats, apoptotic bodies were most common in the group 
treated with etoposide (Fig. 1).
Fig. 1. Bone marrow smears of rats. 
(A) Healthy control rat. (B) Control leukemic rat. Predominant cells are leukemic promyelocytes (arrows) (C) Leukemic 
rat treated with etoposide (50 mg/kg b.w.) for 3 days, from 20 day of leukemia development. Predominant cells are 
mature granulocytes. Arrow indicates apoptotic cell. (D) Leukemic rat pretreated with curcumin (200 mg/kg b.w.) 
for 22 days, followed by co-administration of etoposide (50 mg/kg b.w.) for the last 3 days of experiment. Bone 
marrow precursor cells are visible. May-Grünwald-Giemsa stain. ×1000. Barr = 10 μM.
Administration of curcumin both before and during etoposide treatment led to 
a further but insignificant decrease in the proportion of promyelocytes in com-
parison to the etoposide-only group. The number of promyelocytes seems to re-
turn to normal values in curcumin plus etoposide treated rats, because there is 
an insignificant difference between these group of rats and healthy subjects in 
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terms of the proportion of promyelocytes. In contrast, the number of granulocytic 
precursors (p <0.001), nucleated erythroid cells (p <0.001) and monocytes (p <0.05) 
significantly increased in rats co-administered with curcumin and etoposide in com-
parison to the etoposide-only group (Table 1, Fig. 1). Importantly, the percentage 
of normal granulocytic precursors and mature granulocytes did not differ signifi-
cantly between rats treated with curcumin plus etoposide and the healthy controls. 
DISCUSSION
A major problem in the treatment of AML is still the low level of effectiveness of 
chemotherapy which is caused by the resistance of leukemia cells to conventional 
drugs [24, 25], and the side effects, such as myelotoxicity, which limit its use [26]. 
Neutropenia occurring in newly diagnosed patients with AML may worsen 
during the treatment and then there is an increased risk of bacterial infections, 
which in turn adversely affect the prognosis [26]. 
This paper presents for the first time that curcumin has a synergistic effect 
with etoposide in acute myeloid leukemia cells, while protecting normal hemato-
poietic cells from the cytotoxic effects of etoposide in vivo. Leukemic cells co-exist 
with normal cells of myeloid lineages in BNML rats. It is, therefore, a good model 
for the study of the effects of curcumin and etoposide on cancer cells and their 
normal counterparts in the organism. 
Treatment with etoposide led to a significant decrease in the number of leu-
kemic promyelocytes, and the bone marrow pattern indicated myelosuppression. 
The mature form of granulocytes and lymphocytes prevailed and dramatically 
decreased the number of progenitor cells of normal hematopoiesis (granulocytic 
and erythroid precursors), indicating a strong inhibition of cell cycle progression 
by etoposide. Probably, the reason for the strong myelotoxicity caused by etopo-
side in proliferating bone marrow cells is their high sensitivity to DNA damage 
in the presence of increased activity of topoisomerase II [27]. Etoposide inhibits 
topoisomerase II DNA-cleavable complexes, leading to the formation of DNA strand 
breaks, including the most lethal DNA double-strand breaks (DSBs) [28], resulting 
in apoptosis or necrosis, and consequently myelosuppression. It is believed that 
the myelotoxicity of etoposide corresponds, to a large extent, with the etoposide 
phenoxyl radicals. These radicals can cause a decrease in glutathione levels and 
exacerbate the oxidative damage to DNA and DSBs [28, 29]. On the other hand, 
oxidative damage to mitochondrial membrane phospholipids can result in a loss 
of their integrity, which also leads to cell apoptosis.
It is known that the myelosuppressive effect of etoposide limits the use of 
this chemotherapeutic agent in humans [30]. The limitation of this serious com-
plication associated with etoposide therapy may enable an increase in etoposide 
dosages and thereby improve the effectiveness of the treatment. 
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Slightly different changes occurred in the bone marrow of BNML rats treated 
with curcumin throughout the period of leukemia development. Treatment with 
curcumin from the initial stage of leukemia resembles the situation when the 
disease relapses after remission.
The percentage of promyelocytes decreased significantly in the curcumin-treat-
ed group, although to a lesser extent than after treatment with etoposide. In con-
trast, the percentage of granulocytic precursors increased significantly compared 
to control rats with leukemia. Therefore, the results indicate the cytotoxic action 
of curcumin in promyelocytic leukemia cells and its protective activity in healthy 
myeloid cells. Other studies have shown that polyphenols may increase oxidative 
stress in cancer cells with elevated levels of free radicals [14, 31]. The results 
of previous studies have also demonstrated increased oxidative stress and high 
levels of DSB and oxidative damage to DNA in tissues of BNML rats that cor-
related with the high levels of leukemic cells [16]. Curcumin may be oxidized by 
a myeloperoxidase into phenoxyl radicals in myeloid leukemic cells [32], leading 
to increased oxidative stress and, consequently, to apoptosis.
After co-administration with curcumin and etoposide, the percentage of bone 
marrow cells is normalized, and this group is most similar to healthy animals. The 
percentage of granulocytic precursors, including promyelocytes, mature granulo-
cytes and monocytes, is insignificant in this group compared to healthy controls. 
This observed phenomenon may result from the fact that the rats treated with 
curcumin before the administration of etoposide had more normal hematopoietic 
precursors than animals only treated with etoposide. Other similar results have 
shown that curcumin at a dose of 100 mg/kg b.w. provided protection against 
mitomycin C-induced myelosuppression in mice with a xenogenic transplantable 
model of breast cancer, while causing cytotoxic effects in cancer cells [33]. 
The results of the present study indicate that curcumin alone does not com-
pletely eliminate cancer cells in BNML rats, but it can protect against myelosup-
pression during the use of etoposide. Study of the mechanisms of etoposide in-
teraction with the examined polyphenol may be useful in the prevention of side 
effects caused by this cytostatic drug in normal proliferating cells.
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